湖南南新制药股份有限公司 关于提前归还临时用于补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2025 年 10 月 21 日，公司已累计归还临时补充流动资金的闲置募集 资金人民币 10,000.00 万元。 证券代码：688189 证券简称：南新制药 公告编号：2025-048 一、募集资金临时补充流动资金情况 湖南南新制药股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开 第二届董事会第十四次会议和第二届监事会第十二次会议，审议通过了《关于使 用部分闲置募集资金暂时补充流动资金的议案》。为提高募集资金使用效率，增 加公司收益，减少公司财务费用，降低公司运营成本，维护公司和股东利益，在 确保募集资金投资计划正常进行的前提下，公司决定使用不超过人民币 10,000.00 万元（含本数）闲置募集资金暂时补充流动资金，使用期限为自董事 会审议通过之日起不超过 12 个月，到期归还至募集资金专用账户。在此期间如 遇募集资金专用账户余额不能满足募集资金正常支付的 ...

New Stock Issuance - Xi'an Yicai (787783) issued at a price of 8.62[1] - Changjiang Energy Technology (920158) issued at a price of 5.33[1] Equity Market Alerts - Tender offer for Shangwei New Materials (688585) from September 29, 2025, to October 28, 2025[1] - Significant abnormal fluctuation reported for Nanjing New Pharmaceutical (688189) with a recent announcement on October 10, 2025[1] Recent Announcements - Multiple companies reported significant fluctuations, including ST Yanzhen (603389) with a recent announcement on October 16, 2025[1] - ST Hengjiu (002808) reported a fluctuation with an announcement on October 16, 2025[1] Trading Alerts - A total of 50 companies reported trading alerts with varying degrees of fluctuation, with the highest being 9889 for ST Jianyi (002789) on October 14, 2025[1] - The lowest fluctuation reported was 1,010 for ST Xinyuan (300472) on October 13, 2025[1]

Core Viewpoint - Nanjing Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 23.39% but a recent decline of 11.32% over the past five trading days, indicating volatility in investor sentiment and market performance [1][2]. Group 1: Stock Performance - As of October 16, Nanjing Pharmaceutical's stock price is 8.07 CNY per share, with a market capitalization of 2.214 billion CNY [1]. - The stock has seen a net outflow of 6.2132 million CNY in principal funds, with large orders accounting for 5.73% of total buying and 16.77% of total selling [1]. - The stock has appeared on the daily trading list seven times this year, with the most recent appearance on October 9, where it recorded a net buying of -3.8709 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Nanjing Pharmaceutical reported a revenue of 61.8463 million CNY, a year-on-year decrease of 71.28%, and a net profit attributable to shareholders of -40.0023 million CNY, a decline of 493.23% [2]. - The company has not distributed any dividends in the past three years, with a total payout of 40.74 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 7.02% to 9,464, while the average circulating shares per person decreased by 6.56% to 28,994 shares [2]. - Among the top ten circulating shareholders, Dazheng Jingheng Mixed A holds 2.9738 million shares, with no change in the number of shares held compared to the previous period [3].

New Stock Issuance - New stock issuance includes 泰凯英 (code: 920020) at an issuance price of 7.50 and 超颖电子 (code: 732175) at 17.08[1] Equity Market Alerts - 上纬新材 (code: 688585) is undergoing a tender offer from September 29, 2025, to October 28, 2025[1] - 科思科技 (code: 688788) and 博瑞医药 (code: 688166) have recent announcements dated September 26, 2025, and October 10, 2025, respectively[1] - 南新制药 (code: 688189) reported severe abnormal fluctuations on October 10, 2025[1] Trading Alerts - A total of 50 stocks have trading alerts with the latest announcements on October 15, 2025, including 国光连锁 (code: 605188) and 中持股份 (code: 603903)[1] - The lowest trading alert price recorded is 1,116 for 赛恩斯 (code: 688480)[1]

10月15日，南新制药（维权）盘中上涨2.05%，截至10:02，报7.96元/股，成交2553.57万元，换手率 1.18%，总市值21.84亿元。 资金流向方面，主力资金净流出83.45万元，大单买入448.34万元，占比17.56%，卖出531.79万元，占比 20.83%。 截至6月30日，南新制药股东户数9464.00，较上期增加7.02%；人均流通股28994股，较上期减少 6.56%。2025年1月-6月，南新制药实现营业收入6184.63万元，同比减少71.28%；归母净利润-4000.23万 元，同比减少493.23%。 今年以来南新制药已经7次登上龙虎榜，最近一次登上龙虎榜为10月9日，当日龙虎榜净买入-387.09万 元；买入总计595.43万元 ，占总成交额比20.23%；卖出总计982.51万元 ，占总成交额比33.39%。 资料显示，湖南南新制药股份有限公司位于广东省广州市萝岗区开源大道196号自编1-2栋，成立日期 2006年12月27日，上市日期2020年3月26日，公司主营业务涉及专注于流行性感冒等抗病毒、传染病防 治药品,以及心脑血管疾病、糖尿病等其他重大疾病治疗药品研发、 ...

New Stock Issuance - He Yuan Bio (787765) issued shares at a price of 29.06 on October 14, 2025[1] - The offer period for the acquisition of Shangwei New Materials (688585) is from September 29, 2025, to October 28, 2025[1] Market Alerts - Significant abnormal fluctuations reported for Nanjing New Pharmaceutical (688189) on October 10, 2025[1] - Multiple companies including Hefei Urban Construction (002208) and ST Jianyi (002789) have recent announcements regarding their stock performance[1] Trading Notifications - A total of 30 companies have trading notifications on October 14, 2025, indicating various market activities[1] - Companies such as ST Er Ya (600107) and Guangdong Mingzhu (600382) are among those with recent trading alerts[1]

Group 1 - The core viewpoint of the article emphasizes the increasing protection for small and medium investors by regulatory bodies, including the Supreme People's Court and the China Securities Regulatory Commission (CSRC) [1][3] - The Supreme People's Court has issued a draft interpretation regarding the Company Law, which includes provisions for the return of excessive compensation by executives in cases of financial fraud [3] - The CSRC and the Ministry of Finance have proposed a whistleblower reward system, offering 3% of the penalty amount for each case, with a maximum reward of 1 million yuan [3] Group 2 - Several listed companies, including ST Tian Sheng, Nanxin Pharmaceutical, and others, have faced regulatory penalties or investigations due to information disclosure violations [1][3] - ST Tian Sheng has been flagged for financial fraud, leading to additional risk warnings on its stock trading [4] - Nanxin Pharmaceutical's stock price dropped over 30% following the announcement of an investigation for annual report disclosure violations [5] Group 3 - KJY has been penalized for providing unauthorized guarantees amounting to 150 million yuan without proper board approval [6] - Baiyin Nonferrous Metals received a notice for significant omissions in its annual reports regarding 3 billion yuan in financial products [7] - Hainan Huatie's termination of a 3.69 billion yuan contract has raised regulatory concerns, leading to significant stock price declines [8] Group 4 - Investors affected by the aforementioned companies may be eligible for compensation if they meet specific criteria, such as purchase and sale dates of the stocks [9] - The conditions for potential claims include specific time frames for stock purchases and sales for each company involved [9] - Investors can register their losses through the "Claim Tong" public account and may need to provide documentation such as ID copies and account information [10]

Core Viewpoint - Nanjing New Pharmaceutical is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations in annual report disclosures, linked to frequent accounting errors, including premature revenue recognition and failure to adjust overreported income [3][4][6] Financial Performance - The company reported a significant decline in financial performance, with revenues dropping from 7.44 billion in 2021 to 2.63 billion in 2024, and net profits turning from a profit of 595 million to a loss exceeding 1 billion after accounting adjustments [9][10] - In the first half of 2023, the company achieved revenue of 61.84 million, a decrease of 71.28% year-on-year, and a net loss attributable to shareholders of 40 million [10][11] Accounting Issues - In April 2023, the company acknowledged accounting errors, adjusting 24.54 million in revenue for 2023, which constituted 3.4% of that year's total revenue [4][6] - Historical issues include a 2020 overreporting of income by 58.98 million, which was not adjusted until 2023, violating disclosure regulations [6] Stock Performance and Corporate Actions - The company's stock price experienced a dramatic rise of over 100% in July 2023, followed by a sharp decline of nearly 60% by October 13, 2023, coinciding with the announcement of the investigation [3][8] - Prior to the investigation, the major shareholder announced a plan to reduce holdings, indicating potential insider knowledge of forthcoming issues [8] Industry Context - Nanjing New Pharmaceutical operates in a highly competitive pharmaceutical industry, facing pressures from centralized drug procurement policies and a saturated market for generic drugs, which has led to declining profit margins [11]

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) has signed a joint application agreement with a medical research institution to apply for a national major science and technology project focused on innovative drug development for high-altitude environment-related brain edema and pulmonary hypertension [1] Group 1 - The collaboration aims to strengthen the company's leading position in the cardiovascular disease sector and enhance its innovative drug research and development capabilities [1] - The company plans to continue increasing its investment in innovative drug R&D to improve its competitiveness in this field [1] - As of the first half of 2025, the company's R&D investment reached 47.0095 million yuan, with several projects reaching critical milestones [1] Group 2 - Key projects include the Phase II clinical trial of a Class I innovative drug for diabetic nephropathy, which has completed subject enrollment and is now in the data collection and efficacy evaluation phase [1] - The modified new drug project for inhaled paramivir is currently undergoing Phase III clinical trials, with the clinical trial for drug concentration at the target site completed [1] - The oral lyophilized powder for treating acute ischemic stroke has received a clinical trial notification, and the nebulized solution of levalbuterol has passed on-site verification and has been accepted for market application [1] - Other projects, including acetaminophen mannitol injection, are also progressing in an orderly manner [1] Group 3 - The company is optimizing its product pipeline to leverage existing competitive advantages while exploring potential disease areas, which will enhance the resilience of its product pipeline and positively impact its performance [2] - This strategy is expected to lay a solid foundation for the company's long-term stable development [2]

New Stock Issuance - Marco Polo (Stock Code: 001386) issued at a price of 13.75 on October 13, 2025[1] - New material company (Stock Code: 688585) has a tender offer period from September 29 to October 28, 2025[1] - Zitian (Stock Code: 300280) entered the delisting arrangement period with the last trading day on October 13, 2025[1] Market Alerts - Significant abnormal fluctuations reported for Pinming Technology (Stock Code: 688109) on October 10, 2025[1] - Multiple companies including Kesheng Technology (Stock Code: 688788) and Borui Pharmaceutical (Stock Code: 688166) have recent announcements regarding their stock activities[1] - A total of 30 companies have been flagged for abnormal trading activities, indicating potential market volatility[2]